Medpace Holdings, Inc. Revenue
Medpace Holdings, Inc. (MEDP) reported Revenue of $707.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-23
- Medpace Holdings, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $707.33M, a 17.24% increase year-over-year.
- Medpace Holdings, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $706.60M, a 26.50% increase year-over-year.
- Medpace Holdings, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $708.45M, a 32.03% increase year-over-year.
- Medpace Holdings, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $659.90M, a 23.74% increase year-over-year.
- Medpace Holdings, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $2.53B, a 19.97% increase from fiscal 2024.
- Medpace Holdings, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $2.11B, a 11.84% increase from fiscal 2023.
- Medpace Holdings, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.89B, a 29.17% increase from fiscal 2022.
- Medpace Holdings, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.46B, a 27.80% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $707.33M 10-Q · filed 2026-07-23 | $1.41B 10-Q · filed 2026-07-23 | $2.12B derived: sum of 3 quarters · filed 2026-07-23 | $2.78B derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $706.60M 10-Q · filed 2026-04-23 | $1.42B derived: sum of 2 quarters · filed 2026-04-23 | $2.07B derived: sum of 3 quarters · filed 2026-04-23 | $2.68B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $708.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.37B derived: sum of 2 quarters · filed 2026-02-10 | $1.97B derived: sum of 3 quarters · filed 2026-07-23 | $2.53B 10-K · filed 2026-02-10 |
| 2025-09-30 | $659.90M 10-Q · filed 2025-10-23 | $1.26B derived: sum of 2 quarters · filed 2026-07-23 | $1.82B 10-Q · filed 2025-10-23 | $2.36B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $603.31M 10-Q · filed 2026-07-23 | $1.16B 10-Q · filed 2026-07-23 | $1.70B derived: sum of 3 quarters · filed 2026-07-23 | $2.23B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $558.57M 10-Q · filed 2026-04-23 | $1.10B derived: sum of 2 quarters · filed 2026-04-23 | $1.63B derived: sum of 3 quarters · filed 2026-04-23 | $2.16B derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $536.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.07B derived: sum of 2 quarters · filed 2026-02-10 | $1.60B derived: sum of 3 quarters · filed 2026-02-10 | $2.11B 10-K · filed 2026-02-10 |
| 2024-09-30 | $533.32M 10-Q · filed 2025-10-23 | $1.06B derived: sum of 2 quarters · filed 2025-10-23 | $1.57B 10-Q · filed 2025-10-23 | $2.07B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $528.10M 10-Q · filed 2025-07-22 | $1.04B 10-Q · filed 2025-07-22 | $1.54B derived: sum of 3 quarters · filed 2026-02-10 | $2.03B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $511.04M 10-Q · filed 2025-04-22 | $1.01B derived: sum of 2 quarters · filed 2026-02-10 | $1.50B derived: sum of 3 quarters · filed 2026-02-10 | $1.96B derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $498.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $990.90M derived: sum of 2 quarters · filed 2026-02-10 | $1.45B derived: sum of 3 quarters · filed 2026-02-10 | $1.89B 10-K · filed 2026-02-10 |
| 2023-09-30 | $492.50M 10-Q · filed 2024-10-22 | $953.37M derived: sum of 2 quarters · filed 2024-10-22 | $1.39B 10-Q · filed 2024-10-22 | $1.78B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $460.87M 10-Q · filed 2024-07-23 | $894.94M 10-Q · filed 2024-07-23 | $1.29B derived: sum of 3 quarters · filed 2025-02-11 | $1.67B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $434.07M 10-Q · filed 2024-04-23 | $828.17M derived: sum of 2 quarters · filed 2025-02-11 | $1.21B derived: sum of 3 quarters · filed 2025-02-11 | $1.56B derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $394.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $777.84M derived: sum of 2 quarters · filed 2025-02-11 | $1.13B derived: sum of 3 quarters · filed 2025-02-11 | $1.46B 10-K · filed 2025-02-11 |
| 2022-09-30 | $383.74M 10-Q · filed 2023-10-24 | $734.95M derived: sum of 2 quarters · filed 2023-10-24 | $1.07B 10-Q · filed 2023-10-24 | $1.37B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $351.21M 10-Q · filed 2023-07-25 | $682.15M 10-Q · filed 2023-07-25 | $990.71M derived: sum of 3 quarters · filed 2024-02-13 | $1.29B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $330.95M 10-Q · filed 2023-04-25 | $639.50M derived: sum of 2 quarters · filed 2024-02-13 | $935.07M derived: sum of 3 quarters · filed 2024-02-13 | $1.21B derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $308.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $604.12M derived: sum of 2 quarters · filed 2024-02-13 | $882.41M derived: sum of 3 quarters · filed 2024-02-13 | $1.14B 10-K · filed 2024-02-13 |
| 2021-09-30 | $295.57M 10-Q · filed 2022-10-25 | $573.86M derived: sum of 2 quarters · filed 2022-10-25 | $833.83M 10-Q · filed 2022-10-25 | $1.09B derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $278.29M 10-Q · filed 2022-07-26 | $538.26M 10-Q · filed 2022-07-26 | $797.94M derived: sum of 3 quarters · filed 2023-02-14 | $1.03B derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $259.96M 10-Q · filed 2022-04-26 | $519.64M derived: sum of 2 quarters · filed 2023-02-14 | $750.02M derived: sum of 3 quarters · filed 2023-02-14 | $955.01M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $259.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $490.05M derived: sum of 2 quarters · filed 2023-02-14 | $695.05M derived: sum of 3 quarters · filed 2023-02-14 | $925.92M 10-K · filed 2023-02-14 |
| 2020-09-30 | $230.37M 10-Q · filed 2021-10-26 | $435.37M derived: sum of 2 quarters · filed 2021-10-26 | $666.25M 10-Q · filed 2021-10-26 | $896.13M derived: sum of 4 quarters · filed 2021-10-26 |
| 2020-06-30 | $205.00M 10-Q · filed 2021-07-27 | $435.87M 10-Q · filed 2021-07-27 | $665.76M derived: sum of 3 quarters · filed 2021-07-27 | $882.00M derived: sum of 4 quarters · filed 2021-07-27 |
| 2020-03-31 | $230.88M 10-Q · filed 2021-04-27 | $460.76M derived: sum of 2 quarters · filed 2021-04-27 | $677.00M derived: sum of 3 quarters · filed 2021-04-27 | $891.11M derived: sum of 4 quarters · filed 2021-04-27 |
| 2019-12-31 | $229.89M 10-K · filed 2020-02-25 | $446.12M derived: sum of 2 quarters · filed 2020-10-27 | $660.23M derived: sum of 3 quarters · filed 2020-10-27 | $860.97M 10-K · filed 2022-02-15 |
| 2019-09-30 | $216.24M 10-Q · filed 2020-10-27 | $430.34M derived: sum of 2 quarters · filed 2020-10-27 | $631.08M 10-Q · filed 2020-10-27 | $823.20M derived: sum of 4 quarters · filed 2020-10-27 |
| 2019-06-30 | $214.10M 10-Q · filed 2020-07-28 | $414.85M 10-Q · filed 2020-07-28 | $606.96M derived: sum of 3 quarters · filed 2020-07-28 | $786.21M derived: sum of 4 quarters · filed 2020-07-28 |
| 2019-03-31 | $200.74M 10-Q · filed 2020-04-29 | $392.86M derived: sum of 2 quarters · filed 2020-04-29 | $572.11M derived: sum of 3 quarters · filed 2020-04-29 | $742.25M derived: sum of 4 quarters · filed 2020-04-29 |
| 2018-12-31 | $192.12M 10-K · filed 2020-02-25 | $371.37M derived: sum of 2 quarters · filed 2020-02-25 | $541.51M derived: sum of 3 quarters · filed 2020-02-25 | $704.59M 10-K · filed 2021-02-16 |
| 2018-09-30 | $179.25M 10-K · filed 2020-02-25 | $349.40M derived: sum of 2 quarters · filed 2020-02-25 | $512.47M 10-Q · filed 2019-10-29 | $625.16M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $170.14M 10-K · filed 2020-02-25 | $333.22M 10-Q · filed 2019-07-30 | $445.90M derived: sum of 3 quarters · filed 2020-02-25 | $556.55M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $163.08M 10-K · filed 2020-02-25 | $275.76M derived: sum of 2 quarters · filed 2020-02-25 | $386.40M derived: sum of 3 quarters · filed 2020-02-25 | $492.62M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $112.68M 10-K · filed 2019-02-26 | $223.32M derived: sum of 2 quarters · filed 2019-02-26 | $329.54M derived: sum of 3 quarters · filed 2019-02-26 | $436.15M 10-K · filed 2020-02-25 |
| 2017-09-30 | $110.64M 10-K · filed 2019-02-26 | $216.86M derived: sum of 2 quarters · filed 2019-02-26 | $323.47M 10-Q · filed 2018-10-30 | |
| 2017-06-30 | $106.22M 10-K · filed 2019-02-26 | $212.83M 10-Q · filed 2018-07-31 | ||
| 2017-03-31 | $106.61M 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $421.58M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |